Abnormal Psychology
Body dysmorphic disorder (BDD) is a serious psychiatric illness that is characterized by certain characteristics including an impairing and distressing mental preoccupation with a defect in appearance which is either imagined or merely slight. Individuals that experience this somatoform disorder generally experience extremely impaired functioning in several realms, high rates of suicide attempts and ideation, as well as an overall poor quality of life (Phillips & Pagano, 2006). In addition, the prevalence of BDD is relatively high. Researchers Phillips & Pagano (2006) recognized that the available research examining the effects of pharmacotherapy for individuals with BDD was limited. In response to this limitation, these researchers sought to investigate current and past treatments for BDD using pharmacotherapy and whether these treatments were effective in the alleviation of BDD symptoms. In particular, the researchers described the characteristics of the pharmacotherapy received, examined predictors of treatment with psychotropic medication, determined whether participants revealed their concern
3% of al lifetime medication trials, including SRIs and non-SRIs, were determined to be at least minimally adequate, The likelihood of receiving psychotropic medication was associated with greater lifetime impairment due to the presence of BDD, and increased likelihood of receiving and SRI was linked to lifetime OCD and greater lifetime impairment due to BDD. 4% of SRI trials were considered to be at least minimally adequate for the treatment of BDD, with 12. Methods Participants included in the study were people who presented with DSM-IV BDD and were taking part in naturalistic study that was investigating the clinical course of BDD. s regarding their appearance to the therapist, and the researchers also retrospectively looked at how effectively serotonin re-uptake inhibitors (SRIs) alleviated BDD symptoms. However, most SRI trials were determined as inadequate for the treatment of BDD. Treatments using SRIs that were considered to be adequate and effective were associated with greater improvement in BDD as well as BDD symptoms that were less severe. 9% of the participants had received psychotropic medication at some point in life, and 51% were currently taking these medications. In particular, inclusion criteria for the study were diagnosed lifetime DSM-IV BDD, age 12 and older, and ability to take part in an in-person interview. Furthermore, participants were found to reveal their symptoms of BDD to only 41% of all pharmacotherapists. Discussion A great proportion of participants with BDD were found to have received pharmacotherapy, most prominently SRIs. Chi-square analysis was used to examine between group differences for categorical variables and analysis of variance for continuous variables. Limitations of this study included reliance on participant self-report, the lack of a lifetime measure of BDD severity, and that the representativeness of the sample to the general U. population or other countries was unknown.
Common topics in this essay:
Phillips Pagano,
Global Impressions,
DSM-IV BDD,
Introduction Body,
BDD Form,
Non-Patient Version,
BDD Furthermore,
BDD Treatments,
SRIs SRI,
Methods Participants,
bdd symptoms,
psychotropic medication,
phillips pagano 2006,
treatment bdd,
pagano 2006,
phillips pagano,
minimally adequate,
dsm-iv bdd,
impairment due,
likelihood receiving,
assessment study,
lifetime impairment due,
|
Acceptance Essays
